ALNA - Allena Pharmaceuticals' shares rise 9% after FDA Fast Track status for ALLN-346

Allena Pharmaceuticals (NASDAQ:ALNA) announces that its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. FDA. Shares up more than 9% premarket. ALLN-346 is in Phase 2 development for the treatment of hyperuricemia in gout patients with advanced chronic kidney disease (CKD). Fast Track is an FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Once a drug receives Fast Track designation, early and frequent communication between the FDA and the sponsor is encouraged throughout the entire drug development and review process.

For further details see:

Allena Pharmaceuticals' shares rise 9% after FDA Fast Track status for ALLN-346